Medicin

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
···

AbbVie-aktie (ABBV): FDA godkender ny Venclexta-Calquence-kombination til CLL — det skal du holde øje med mandag

The FDA approved a new first-line combination therapy for chronic lymphocytic leukemia using AbbVie’s Venclexta and AstraZeneca’s Calquence, showing improved progression-free survival over standard chemoimmunotherapy. AbbVie shares closed up 0.21% at $224.81 on Friday. Barclays initiated coverage with an overweight rating and $275 price target. Investors await market reaction when trading resumes Monday.
februar 23, 2026

Stock Market Today

  • ASX Board Independence Model Under Scrutiny for Value Destruction
    May 24, 2026, 1:16 AM EDT. Recent reports highlight failures in the Australian Securities Exchange (ASX) governance model, particularly its approach to board independence. Experts Dimitri Burshtein and Peter Swan argue that the current system prioritizes box-ticking over genuine value creation, evidenced by costly acquisitions by major firms like CSL, Orora, and James Hardie. The Australian Council of Superannuation Investors faces calls to reevaluate governance practices amid growing concerns that poor oversight is leading to billions in shareholder value loss. The debate centers on whether Australian companies can curb this trend by adopting more effective board responsibilities and decision-making frameworks.